Innovation, Access, and the Future of Cardiac Care
MD Newsline
In this episode of MD Newsline, Dr. Quentin Youmans, a heart failure cardiologist at Northwestern Medicine, explores the rapidly evolving landscape of advanced heart failure care. He shares insights into guideline-directed medical therapy, emerging device-based interventions, and the growing role of personalized medicine in improving outcomes for patients with complex cardiovascular disease. Dr. Youmans also addresses health disparities, access challenges, and the importance of multidisciplinary collaboration in modern cardiology. Episode Highlights Advances in Guideline-Directed Medical...
info_outline
From Awareness to Action: Cancer Prevention & Patient Empowerment
MD Newsline
In this episode of MD Newsline, Dr. Aruna Anupindi, a consultant clinical oncologist based in Oxford, UK, joins the podcast to discuss evolving trends in breast and prostate cancer care. Specializing in breast and urological cancers, Dr. Anupindi shares insights from her clinical practice, highlights key takeaways from recent oncology conferences, and reflects on the growing importance of early detection, personalized therapies, and quality of life in cancer treatment. She also addresses disparities in screening uptake, emerging treatment strategies aimed at reducing chemotherapy exposure,...
info_outline
AI in Oncology: Building Smarter Clinical Trials and Closing Data Gaps
MD Newsline
In this episode of MD Newsline, Dr. Arsela Prelaj, a thoracic oncologist and AI researcher at the Istituto Nazionale dei Tumori in Milan, Italy, explores the rapidly evolving role of artificial intelligence in oncology. Drawing from her background in medical oncology and bioengineering, Dr. Prelaj discusses how AI is revolutionizing clinical trial design, improving trial success rates, and expanding patient access to innovative therapies. She shares real-world examples of how machine learning, large language models, and synthetic data are being integrated into cancer research, while also...
info_outline
How Parity and Breastfeeding May Guard Against Triple-Negative Breast Cancer
MD Newsline
In this episode of MD Newsline, Dr. Sherene Loi, a medical oncologist and laboratory head at the Peter MacCallum Cancer Centre in Melbourne, Australia, discusses groundbreaking research published in Nature exploring how pregnancy and breastfeeding influence immune protection against triple-negative breast cancer. Dr. Loi shares insights into how reproductive history reshapes the immune system, particularly T cell activity, and how these findings may inform future prevention strategies, screening approaches, and immunotherapy development. Episode Highlights: The Immune System’s Role in...
info_outline
Axial Spondyloarthritis: From Inflammatory Back Pain to Targeted Therapy
MD Newsline
In this episode of MD Newsline, Dr. Joel Wright, a rheumatology fellow at UCLA, provides an in-depth, practical discussion on axial spondyloarthritis and related spondyloarthritides. Dr. Wright breaks down evolving disease definitions, diagnostic challenges, imaging interpretation, and modern treatment strategies, while emphasizing a holistic, patient-centered approach to care. The conversation highlights how early recognition and individualized therapy can significantly improve long-term outcomes. Episode Highlights Defining Axial vs. Peripheral Spondyloarthritis Dr. Wright explains the...
info_outline
Vitamin D, Epstein-Barr Virus, and MS Risk
MD Newsline
In this episode of MD Newsline, Dr. Marianna Cortese, a medical doctor and epidemiologist at the Harvard T.H. Chan School of Public Health, shares groundbreaking research on the link between vitamin D, Epstein-Barr virus (EBV), and the risk of multiple sclerosis (MS). Her work, conducted within the U.S. military cohort, sheds new light on racial, genetic, and environmental factors influencing MS development and potential prevention strategies. Dr. Cortese discusses how vitamin D levels and immune response modulation play a role in MS prevention, and how EBV infection—now recognized as the...
info_outline
Living With HS: Tameka Carter’s Journey to Diagnosis and Treatment
MD Newsline
In this episode of MD Newsline, patient advocate Tameka Carter shares her personal journey living with hidradenitis suppurativa (HS), a chronic, painful inflammatory skin condition often misdiagnosed for years. Tameka discusses the early signs of HS, the emotional and physical toll of delayed diagnosis, and the importance of finding a specialist who truly listens. She offers valuable insight into treatment decision-making, lifestyle changes, and the critical role of self-advocacy in managing a lifelong condition. Episode Highlights Early Symptoms and Delayed Diagnosis Tameka reflects on...
info_outline
How Ultra-Processed Food Impacts MS Progression
MD Newsline
In this episode of MD Newsline, Dr. Gloria Dalla Costa, a researcher at Harvard University, shares groundbreaking insights into the role of ultra-processed foods in multiple sclerosis (MS) progression. Drawing from her research on environmental and metabolic risk factors, Dr. Dalla Costa discusses how dietary habits may influence inflammation, disease activity, and long-term neurological outcomes in MS patients. Her work reveals compelling evidence that higher consumption of ultra-processed foods correlates with increased inflammatory markers, worsened MRI outcomes, and a greater risk of...
info_outline
Biomarkers in Multiple Sclerosis: Tracking Disease Progression
MD Newsline
In this episode of MD Newsline, Dr. Ahmed Abdelhak, Assistant Professor of Neurology at the University of California, San Francisco, explores the cutting-edge world of fluid biomarkers in multiple sclerosis (MS). With over a decade of experience as an MS clinical scientist, Dr. Abdelhak shares his expertise on the evolving role of biomarkers in understanding, predicting, and managing MS progression. He breaks down how markers like neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and chitinase (CHIT1/CHIT3) offer insights into the underlying neuroinflammatory and...
info_outline
Optic Neuritis, MS Differentials, and Modern Treatment Pathways
MD Newsline
In this episode of MD Newsline, Dr. Nilüfer Kale, Head of the Department of Neurology at Başakşehir Çam and Sakura City Hospital in Istanbul, Turkey, provides an in-depth look into optic neuritis, multiple sclerosis (MS), and related demyelinating disorders. She discusses the pathophysiology, diagnostic challenges, and treatment evolution of these conditions—offering valuable insights for clinicians managing autoimmune neuroinflammatory diseases. Dr. Kale also highlights the importance of accurate differential diagnosis, the role of neuroimaging and biomarkers, and how advancements in...
info_outlineIn this episode of MD Newsline, Dr. Elias Jabbour, Professor of Medicine at MD Anderson Cancer Center, shares groundbreaking insights into the evolving treatment landscape of chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). He discusses the transformative role of tyrosine kinase inhibitors (TKIs), strategies to achieve treatment-free remission, and how genetic testing, CAR-T therapy, and monoclonal antibodies are reshaping frontline and relapsed leukemia management.
Episode Highlights:The TKI Revolution in CML Dr. Jabbour recounts how TKIs have shifted CML from a fatal disease to one with normal life expectancy, even allowing for treatment discontinuation in select patients after prolonged deep molecular remission. He explains how monitoring and response milestones guide therapy and when mutation testing is necessary.
Understanding Resistance and Personalized Care Resistance to TKIs is rare when patients are compliant. Dr. Jabbour outlines how NGS is used to detect kinase domain mutations and guide next-line therapy, particularly in BCR-ABL-independent resistance. He also shares why genomic profiling isn't yet used for frontline CML treatment but may become more relevant in advanced disease.
Integrating Immunotherapy in ALL In adult ALL, Dr. Jabbour explains how immunotherapy and TKIs are reducing the need for chemotherapy and transplantation, improving both survival and quality of life. He discusses how CAR-T therapy may move to the frontline setting to shorten treatment duration and potentially eliminate the need for allogeneic transplant.
AML: Moving Toward Targeted Frontline Therapy Dr. Jabbour outlines how FLT3, IDH, and menin inhibitors are improving outcomes in AML, especially when combined with hypomethylating agents and venetoclax. He stresses the importance of minimal residual disease (MRD) monitoring to tailor therapy and reduce overtreatment.
Overcoming Barriers and Promoting Access He reflects on challenges like drug cost, limited access to specialized care, and clinical trial barriers such as travel and housing. Dr. Jabbour calls for simplified regimens that can be delivered anywhere, so that all patients—not just those at top centers—can benefit from the latest innovations.
Key Takeaway:
With the right combinations of targeted therapies, immunotherapies, and patient-specific monitoring, many leukemias—especially CML and ALL—are becoming manageable or even curable. But equitable access, affordability, and ongoing collaboration are essential to truly transform care worldwide.
Resources:
Website: https://mdnewsline.com Newsletter: https://mdnewsline.com/subscribe Connect with Dr. Elias Jabbour: MD Anderson ProfileHosted on Acast. See acast.com/privacy for more information.